Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
Status:
Terminated
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the
isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate
Alzheimer's disease.